NAD-dependent protein deacetylase, which deacetylates internal lysines on histone and non-histone proteins. Deacetylates 'Lys-40' of alpha-tubulin. Involved in the control of mitotic exit in the cell cycle, probably via its role in the regulation of cytoskeleton. Deacetylates PCK1, opposing proteasomal degradation. Deacetylates 'Lys-310' of RELA. Interacts with HDAC6, suggesting that these proteins belong to a large complex that deacetylate the cytoskeleton. Widely expressed. Highly expressed in heart, brain and skeletal muscle, while it is weakly expressed in placenta and lung. Down-regulated in many gliomas suggesting that it may act as a tumor suppressor gene in human gliomas possibly through the regulation of microtubule network. Inhibited by Sirtinol, A3 and M15 small molecules. Inhibited by nicotinamide. Belongs to the sirtuin family. Class I subfamily. 4 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Biological Process: chromatin silencing at rDNA; mitosis; proteasomal ubiquitin-dependent protein catabolic process; regulation of phosphorylation; chromatin silencing; regulation of exit from mitosis; response to redox state; histone deacetylation; gene silencing; negative regulation of striated muscle development; chromatin silencing at telomere; protein amino acid ADP-ribosylation; protein amino acid deacetylation; cell division; negative regulation of transcription, DNA-dependent
Alt. Names/Synonyms: NAD-dependent deacetylase sirtuin-2; silencing information regulator 2-like; silent information regulator 2; SIR2; SIR2-like protein 2; sir2-related protein type 2; SIR2L; SIR2L2; SIRT2; sirtuin (silent mating type information regulation 2 homolog) 2 (S. cerevisiae); sirtuin type 2
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.